Skip to main content

Table 1 Study characteristics and input data for 20 trials included in the NMA

From: Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis

Study (Source) Treatment Arms N Male Age, y Baseline mean CD4+, cells/mL (SD) Baseline mean viral load, log10 RNA copies/mL, (SD) N with Virologic Suppression HIV RNA < 50 copies/mL (r/n) CD4+ change, cells/μL AEs (r/n) Drug-related AEs (r/n) Serious AEs (r/n) Discontin-uations (r/n)
ACTG A5257 ([15]) ATV/r + TDF/FTC 605 76.20 37 309 4.60a 379/605 280 489/605 89/605
DRV/r + TDF/FTC 601 76.21 37 310 4.61a 437/601 256 390/601 101/601
RAL + TDF/FTC 603 75.46 36 304 4.66a 481/603 288 359/603 72/603
ECHO + THRIVE [16] EFV + TDF/FTC 546 78.94 36 261a 5.0a 422/546 222 61/546
RPV + TDF/FTC 550 78.00 36 247a 5.0a 423/550 226 52/550
FLAMINGO (CSR) [17] DRV/r + ABC/3TC 242 83.06 34 400a 4.48a 60/80 274.4 (SD:226.64) 217/242 124/242 21/242 52/242
DRV/r + TDF/FTC 104/162
DTG + ABC/3TC 242 87.19 34 390a 4.49a 65/79 298.2 (SD:199.95) 222/242 83/242 36/242 34/242
DTG + TDF/FTC 129/163
GS-236-0102 [18] EFV + TDF/FTC 352 89.77 38 382 (170.2) 4.78 (0.6) 287/352 273 61/352
EVG/c + TDF/FTC 348 88.22 38 391 (188.6) 4.73 (0.6) 293/348 295 53/348
GS-US-380-1489 [19] BIC + TAF/FTC 314 90.76 31 443a 4.42a 276/314 287 (SD:207) 292/314 89/314 36/314 36/314
DTG + ABC/3TC 315 89.52 32 450a 4.51a 283/315 288 (SD: 247) 302/315 127/315 39/315 31/315
GS-US-380-1490 [20] BIC + TAF/FTC 320 87.50 33 440a 4.43a 269/320 237 (SD:204) 283/320 64/320 55/320 48/320
DTG + TAF/FTC 325 88.62 34 441a 4.45a 281/325 281 (SD:209) 288/325 92/325 33/325 36/325
SINGLE (CSR) [21] DTG + ABC/3TC 414 83.82 36 334.5a 4.67a 332/414 325.3 (SE:10.46) 376/414 184/414 44/414 72/414
EFV + TDF/FTC 419 84.96 35 339a 4.7a 303/419 281.4 (SE:10.87) 394/419 282/419 51/419 109/419
SPRING-2 (CSR) [22] DTG + ABC/3TC 411 84.67 37 359a 4.52a 125/169 292.2 (SD:195.70) 349/411 124/411 41/411 62/411
DTG + TDF/FTC 207/242
RAL + ABC/3TC 411 86.37 35 362a 4.58a 124/164 286.2 (SD:192.45) 349/411 121/411 48/411 79/411
RAL + TDF/FTC 190/247
STaR (GS-US-264-0110)
[23]
EFV + TDF/FTC 392 92.86 35 385 (187) 4.8 (0.6) 284/392 259 (SD:191) 368/392b 102/392
RPV + TDF/FTC 394 92.89 37 396 (180) 4.8 (0.7) 307/394 278 (SD:189) 362/394b 78/394
STARMRK [24] EFV + TDF/FTC 282 81.91 36.9 217.4 (133.6) 5 (0.6) 223/282 224.8 275/282 220/282 34/282 50/282
RAL + TDF/FTC 281 80.78 37.6 218.9 (124.2) 5.0 (0.6) 228/281 239.6 266/281 132/281 40/281 36/281
934 study [25] EFV + 3TC/ZDV 254 87.01 37 241a 5.0a 237 (SD: 136.4) 180/254
EFV + TDF/FTC 255 85.88 36 233a 5.0a 270 (SD: 147.5) 185/257
ABCDE study [26] EFV + ABC/3TC 115 74.8 38.4 203 (167) 4.94 (0.60) 70/115 263 40/115
EFV + 3TC/d4T 122 78.7 38.5 223 (177) 4.92 (0.57) 58/122 294 59/122
ACTG A5142 [27] EFV + CHOICE 250 81.20 39 195 4.8 158/178 230
LPV/r + CHOICE 253 76.68 37 190 4.8 136/177 287
ACTG A5202 [28] (Clinicaltrials.gov) ATV/r + ABC/3TC 463 83.80 38 236a 4.7 (0.7) 250.3a 141/463
ATV/r + TDF/FTC 465 83.23 38.9 224a 4.7 (0.7) 251.5a 123/465
EFV + ABC/3TC 465 78.92 38.4 225a 4.7 (0.7) 250.5a 141/465
EFV + TDF/FTC 464 84.70 38.2 234a 4.7 (0.7) 220.5a 121/464
ARTEMIS [29] DRV/r + TDF/FTC 343 69.68 36 228a 7.1a 271/343 171a 34/343 59/343
LPV/r + TDF/FTC 346 69.65 35 218a 6.2a 246/346 188a 55/346 81/346
ASSERT [30] EFV + TDF/FTC 193 79.79 36 230a 5.12a 76/128 220a 59/193
EFV + ABC/3TC 192 82.81 38 240a 5.01a 57/112 235a 77/192
ATADAR [31] ATV/r + TDF/FTC 90 86.67 35 328 (205) 4.8 (0.7) 284 (SD:219) 24/90
DRV/r + TDF/FTC 88 88.64 37 341 (171) 4.8 (0.8) 298 (SD: 182) 7/88
CASTLE [32] ATV/r + TDF/FTC 440 68.64 34 205 5.01 308/440 268 355/441 61/441 72/438
LPV/r + TDF/FTC 443 68.62 36 204 4.96 281/443 290 370/437 48/437 95/440
GS-236-0103 [33] ATV/r + TDF/FTC 355 89.01 39 366a 4.8 (0.62) 292/355 261 50/355 55/355
EVG/c + TDF/FTC 353 91.78 38 351a 4.8 (0.61) 294/353 256 34/353 49/353
HEAT ([34], clinicaltrials.gov) LPV/r + ABC/3TC 343 83.97 38 214a 4.903a 206/343 250a 274/343 42/343 109/343
LPV/r + TDF/FTC 345 80.00 38 193a 4.844a 200/345 246.5a 276/345 45/345 124/345
  1. a Median was used instead of mean
  2. b Reported as treatment emergent adverse events, assumed to be equivalent to other reported AEs